Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Revive Therapeutics Ltd. C.RVV

Alternate Symbol(s):  RVVTF

Healthcare
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. The Company’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the Company was granted Food and Drug Administration (FDA) orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.


CSE:RVV - Post by User

Revive Therapeutics Ltd.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(47)
•••
Post by Trippedstockson Dec 03, 2021 3:45pm
193 Views
Post# 34196503

South Korea getting ready for EUA.

South Korea getting ready for EUA.
https://m.nspna.com/news/?mode=view&newsid=541717

so 8000 won for 5 day treatment.

"bushiramine is priced at $0.5 per limited, and is only $7.5 (about 8,000 won) for 5 days based on taking 3 times a day."

Based on PR saying 5,000,000,000 pills in 2022, 15 pills a person, assume 333 million patients at $8.69(8000 Won at today's exchange rate)

That's sales at $2.8 billion. Times 5. $14.5 billion = $35+ SP
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities